Insulin aspart (AT278) vs THDB0206
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: Insulin receptor · full Type 2 Diabetes pipeline
Insulin aspart (AT278)
Developed by Arecor Limited
NCT05754424 · Phase 1 · completed
Every participant received AT278 and the active comparator insulin in random order, with neither participants nor staff knowing which was given at each visit, which is a solid design. But the trial measured a pharmacology lab readout rather than a real-world blood sugar or complication outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Reported efficacy
Area under the glucose infusion rate-time curve of insulin aspart (0 to 60 minutes): Glucose clamp trial in overweight/obese people with Type 2 Diabetes (NCT05754424, AT278 U500 vs NovoRapid U100 vs Humulin R U500, 41 participants per EASD 2024 data matching registry enrollment): primary non-inferiority endpoint met with statistical superiority -- 1.7-fold higher glucose-lowering effect in first 60 min (95% CI 1.32-2.96, p<0.0001). (met)
Result source: NCT05754424
THDB0206
Developed by Adocia and partners
NCT05834868 · Phase 3 · completed
The study was randomized and actively controlled with insulin lispro, but it was open-label and used change in HbA1c as its primary, surrogate endpoint rather than a hard clinical outcome. Registry results are not posted; the sponsors (Adocia and Tonghua Dongbao) announced positive topline results versus Humalog in July 2025, so the result rests on a company announcement.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Results for Type 2 Diabetes
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Insulin aspart (AT278) | THDB0206 |
|---|---|---|
| HbA1c, change | —Not reported | —Not posted · NCT05834868 |
| Body weight, change (kg) | —Not reported | —Not posted · NCT05834868 |
| HbA1c below 7% | —Not reported | —Not posted · NCT05834868 |
| Fasting plasma glucose, change | —Not reported | —Not posted · NCT05834868 |
| 3-point MACE (% with event) | —Not reported | —Not posted · NCT05834868 |
HbA1c, change
- Insulin aspart (AT278)
- —Not reported
- THDB0206
- —Not posted · NCT05834868
Body weight, change (kg)
- Insulin aspart (AT278)
- —Not reported
- THDB0206
- —Not posted · NCT05834868
HbA1c below 7%
- Insulin aspart (AT278)
- —Not reported
- THDB0206
- —Not posted · NCT05834868
Fasting plasma glucose, change
- Insulin aspart (AT278)
- —Not reported
- THDB0206
- —Not posted · NCT05834868
3-point MACE (% with event)
- Insulin aspart (AT278)
- —Not reported
- THDB0206
- —Not posted · NCT05834868
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
THDB0206: no structured comparison results are available for Type 2 Diabetes.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Insulin aspart (AT278)'s landscape · THDB0206's landscape